Choices in IgG replacement therapy for primary immune deficiency diseases: Subcutaneous IgG vs. intravenous IgG and selecting an optimal dose

Current Opinion in Allergy and Clinical Immunology

Volumn 11, Issue 6, 2011, Pages 532-538

  Berger, Melvin ^a,b  

^a CSL Behring LLC   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

IgG therapy; intravenous IgG; pharmacokinetics; primary immune deficiency diseases; subcutaneous IgG

Indexed keywords

IMMUNOGLOBULIN G;

AREA UNDER THE CURVE; BURNING SENSATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; HUMAN; IMMUNE DEFICIENCY; PRIMARY IMMUNE DEFICIENCY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; SKIN REDNESS; STEADY STATE; SUBSTITUTION THERAPY; SWELLING;

BIOLOGICAL AVAILABILITY; DRUG DOSAGE CALCULATIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; PATIENT PREFERENCE;

EID: 80255138210     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32834c22da     Document Type: Review

References (40)

1. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin N Am 2008; 28:779-802.
2. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin N Amer 2008; 28:803-819.
3. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011; 139:133-134.
4. Bexon M, Rojavin M, Jolles S, et al. The construction of a pharmacokinetic model to describe intravenous and subcutaneous supplementation of IgG in patients with primary immunodeficiency. J Allergy Clin Immunol 2011; 127:AB16.
5. Berger M. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Reports 2002; 2:368-378.
6. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008; 28:737-764.
7. Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Int Med 1980; 93:55-56.
8. Welch MJ, Stiehm ER. Slow subcutaneous immunoglobulin therapy in a patient with reactions to IM immunoglobulin. J Clin Immunol 1983; 3:285-286.
9. Ochs HD, Gupta S, Kiessling P, et al. Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26:265-273.
10. Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J of Clin Immunol 2011; 31:323-331.
11. Wasserman RL, Irani AM, Tracy J, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol 2010; 161:518-526.
12. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010; 30:734-745.
13. Immune Deficiency Foundation Treatment experiences and preferences of patients with primary immune deficiency diseases: first national survey. 2003, available at: www.primaryimmune.org/publications/surveys/Treatment-experiences- and-preferences-(2003).
14. EMA. Note for guidance on the investigation of normal human immunoglobulin for subcutaneous and intramuscular use. CPMP/BPWG/283/00, 2002. www.ema.europa.eu/pdfs/human.bpwg/028300.en.pdf.
15. BallowM. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38:122-132.
16. Waniewski J, Gardulf A, Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immune deficiency. J Clin Immunol 1994; 14:90-97.
17. Borte, M, I. Quinti, A. Sorensina, et al. Efficacy and safety of subcutaneous Vivaglobin1 replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J Clin Immunol 2011 (in press).
18. Wang W, Wang EQ, Balthasar JP, et al. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548-558.
19. Aebersold P. Intravenous immunoglobulins in the 21st century: progress and challenges in efficacy, safety and paths to licensure. FDA workshop 4/13/05. www.fda.gov/cber/minutes/igiv041305t.htm.
20. Bonilla FA IgG Replacement therapy, No size fits all. Clin Immunol 2011. doi: 10.1016/j. clim.2011.02.020.
21. US FDA. Guidance for Industry: safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. Available at: http://www.fda.- gov/cber/gdlns/igivimmuno.htm.
22. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008; 122:210-212.
23. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125:1354-1360.
24. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010; 137:21-30.
25. Berger M. Incidence of Infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD. J Clin Immunol (Epub ahead of print).
26. Chen Y, Stirling RG, Paul E, et al. Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies. J Allergy Clin Immunol 2011; 127:1414-1417.
27. Wasserman RL. Common infusion-related reactions to subcutaneous immunoglobulin therapy: managing patient expectations. Patient Prefer Adherence 2008; 2:163-166.
28. Desai SH, Chouksey A, Poll J, Berger M. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously. J Allergy Clin Immunol 2009; 124:854-856.
29. Hansen S, Gustafson R, Smith CI, Gardulf A. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety Clin. Immunol 2002; 104:237-241.
30. Chouksey A, Duff K, Wasserbauer N, Berger M. Subcutaneous immunoglobulin- g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens. Allergy Asthma Clin Immunol 2005; 1:120-130.
31. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol2010; 30:301-307.
32. Knight E, Carne E, Novak B, et al. Self-administered hyaluronidase- facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency. J Clin Pathol 2010; 63:846-847.
33. Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006; 26:65-72.
34. Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114:936-942.
35. Kittner JM, Grimbacher B, Wulff W, et al. Patients attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol 2006; 26:400-405.
36. Borte M, Pac M, Serban M, et al. Efficacy and safety of Hizentra(1), a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. J Clin Immunol2011. [Epub aheadof print]
37. Church JA, Howard V, Sleasman JM, et al. Subcutaneous IgG replacement therapy in infants and children with primary immunodeficiencies. J Allergy Clin Immunol 2011; 127:AB213.
38. Stein MR, Koterba A, Rodden L, Berger M. Safety and efficacy of homebased subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases. Postgrad Medicine 2011; 123:186-193.
39. Ho C, Membe S, Cimon K, et al. An overview of subcutaneous vs. intravenous immunoglobulin for primary immunodeficiencies: systematic review and economic analysis [Technology overview #36] Canadian Agency for Drugs and Technologies in Health, 2008. www.cadth.ca/index.php./en/publication/785.
40. Ducruet T, M-C Levasseur, A Des Roches, et al. Treatment costs associated with hospital/-based IVIG therapy compared to home-based SCIG therapy in a cohort of patients with primary immunodeficiency. J Clin Immunol 2011.